Our President and CEO, Luis Pena, will be in Miami on December 4-5th for?the 7th Annual Evercore ISI HealthCONx Conference and?Citi’s 2024 Global Healthcare Conference. We hope to see you there!
Evommune
生物技术研究
Palo Alto，California 2,953 位关注者
Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease.
关于我们
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
- 网站
-
www.evommune.com
Evommune的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Palo Alto，California
- 类型
- 私人持股
- 创立
- 2020
- 领域
- Chronic Disease、Inflammatory Disease、Biotechnology、Medicines、Patient Care和Research and Development
地点
-
主要
获取路线
US，California，Palo Alto
Evommune员工
动态
-
WeWillCure.com article on our Series C raise and innovative pipeline.
-
Thanks to Nasdaq for highlighting our Series C financing and to our mission to do something about chronic inflammation. #biotech #biotechnology #lifescience
-
-
Evommune转发了
Today, we announced the closing of a $115 million Series C financing co-led by new investors?RA Capital Management and Sectoral Asset Management, with participation from?additional?new plus?existing investors. We also welcomed Derek DiRocco, PhD and Fran?ois Beaubien, Ph.D. to our Board of Directors.?Proceeds will be used to support the advancement of our lead clinical programs in chronic urticaria and atopic dermatitis. Learn more: https://lnkd.in/gzjbRSUA #immunology #inflammation #urticaria #biotechnology
-
Thanks to New York Stock Exchange #NYSE for recognizing our $115 million Series C financing. #biotech #lifescience #biotechnology
-
-
Today, we announced the closing of a $115 million Series C financing co-led by new investors?RA Capital Management and Sectoral Asset Management, with participation from?additional?new plus?existing investors. We also welcomed Derek DiRocco, PhD and Fran?ois Beaubien, Ph.D. to our Board of Directors.?Proceeds will be used to support the advancement of our lead clinical programs in chronic urticaria and atopic dermatitis. Learn more: https://lnkd.in/gzjbRSUA #immunology #inflammation #urticaria #biotechnology
-
Evommune转发了
Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG
How Evommune is Redefining Treatments for Chronic Inflammatory and Autoimmune Diseases
wewillcure.com
-
Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG
How Evommune is Redefining Treatments for Chronic Inflammatory and Autoimmune Diseases
wewillcure.com
-
Evommune wishes to congratulate Eli Lilly on obtaining FDA approval for Ebglyss? (lebrikizumab-ibkz). Several of our current Evommune colleagues played a role in its development, and are proud of its approval. Our drive to continue to deliver meaningful new medicines to patients has never been stronger.?Chronic inflammation destroys lives and Evommune is here to do something about it! https://lnkd.in/gzKkPXi7
FDA approves Lilly's eczema drug Ebglyss for moderate-to-severe disease
endpts.com